Renaissance Technologies's ADMA Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 2.8M shares of ADMA Biologics, Inc. (ADMA) worth $40.61 M, representing 0.05% of the portfolio. First purchased in 2017-Q2, this long-term strategic position has been held for 34 quarters.
Based on 13F filings, Renaissance Technologies has maintained a strategic position in ADMA, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2024, adding 1.1M shares. Largest reduction occurred in Q2 2025, reducing 402.9K shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's ADMA Biologics (ADMA) Holding Value Over Time
Track share changes against reported price movement
Quarterly ADMA Biologics (ADMA) Trades by Renaissance Technologies
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2017 | +11,300 | New Buy | 11,300 | $3.72 |
| Q3 2017 | +9,000 | Add 79.65% | 20,300 | $3.10 |
| Q4 2017 | -20,300 | Sold Out | 20,300 | $0.00 |
| Q2 2018 | +29,200 | New Buy | 29,200 | $4.52 |
| Q3 2018 | +159,100 | Add 544.86% | 188,300 | $6.21 |
| Q4 2018 | -188,300 | Sold Out | 188,300 | $0.00 |
| Q2 2021 | +175,626 | New Buy | 175,626 | $1.60 |
| Q3 2021 | +59,374 | Add 33.81% | 235,000 | $1.13 |
| Q4 2021 | +113,900 | Add 48.47% | 348,900 | $1.41 |
| Q1 2022 | +177,800 | Add 50.96% | 526,700 | $1.83 |
| Q2 2022 | +198,800 | Add 37.74% | 725,500 | $1.98 |
| Q3 2022 | -87,100 | Reduce 12.01% | 638,400 | $2.43 |
| Q4 2022 | +57,535 | Add 9.01% | 695,935 | $0.00 |
| Q1 2023 | +277,300 | Add 39.85% | 973,235 | $0.00 |
| Q2 2023 | +240,500 | Add 24.71% | 1.21 M | $0.00 |
| Q3 2023 | +182,820 | Add 15.06% | 1.4 M | $3.58 |
| Q4 2023 | -338,620 | Reduce 24.25% | 1.06 M | $4.52 |
| Q1 2024 | +949,100 | Add 89.71% | 2.01 M | $6.60 |
| Q2 2024 | +575,100 | Add 28.65% | 2.58 M | $11.18 |
| Q3 2024 | +1.09 M | Add 42.02% | 3.67 M | $19.99 |
| Q4 2024 | +102,692 | Add 2.80% | 3.77 M | $17.15 |
| Q1 2025 | -220,900 | Reduce 5.86% | 3.55 M | $19.84 |
| Q2 2025 | -402,935 | Reduce 11.35% | 3.15 M | $18.21 |
| Q3 2025 | -375,611 | Reduce 11.94% | 2.77 M | $14.66 |
Renaissance Technologies's ADMA Biologics Investment FAQs
Renaissance Technologies first purchased ADMA Biologics, Inc. (ADMA) in Q2 2017, acquiring 11,300 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held ADMA Biologics, Inc. (ADMA) for 34 quarters since Q2 2017. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's largest addition to ADMA Biologics, Inc. (ADMA) was in Q3 2024, adding 3,667,196 shares worth $73.31 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 2,770,442 shares of ADMA Biologics, Inc. (ADMA), valued at approximately $40.61 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, ADMA Biologics, Inc. (ADMA) represents approximately 0.05% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's peak holding in ADMA Biologics, Inc. (ADMA) was 3,769,888 shares, as reported at the end of Q4 2024. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.